Seven-Year Legal Challenge To Japan’s OTC Online Sales Ban Fails
Executive Summary
Japan’s Supreme Court has delivered a final ruling on a seven year dispute over online sales of non-prescription medicines. The Court has rejected a complaint against the ban on distant selling of OTCs in the most-strictly-regulated category, that of recently switched drugs. Meanwhile, the Japanese government is extending the country’s Self-Medication Tax Deduction System for another five years.
You may also be interested in...
Japan Embarks On Rx-To-OTC Switch Revolution
The Japanese government has approved a raft of measures aimed at expanding the country's consumer health market, including reforms to an Evaluation Committee that has not lived up to its promise of expediting Rx-to-OTC switches.
Asia’s OTC Market Stunted By Regulatory Disharmony
HBW Insight Exclusive: A lack of regulatory harmonization, especially with regards to Rx-to-OTC switch, is holding the Asia-Pacific OTC market back, according to APSMI secretary general, Toshi Tominaga.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.